NEW DELHI : The Drug Controller General of India (DCGI) has given approval to Hetero, a generic pharmaceutical company for manufacturing and marketing of the investigational antiviral medicine ‘Remdesivir’ from for the treatment of Covid-19.Hetero’s generic version of Remdesivir will be marketed under the brand name ‘COVIFOR’ in India.“In the light of increasing covid-19 cases in India, the approval of ‘COVIFOR’ (Remdesivir) can prove to be a game-changer given its positive clinical outcomes," Dr B Partha Saradhi Reddy, Chairman, Hetero Group of Companies said.“Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country.
Read more on livemint.com